This issue features articles on the firm’s Business Advisory Practice supporting Nervosave Therapeutics’ U.S. expansion; the USPTO’s forthcoming guidance on AI innovation protection; option pool sizes for life sciences companies; life sciences venture financings for clients in 2H 2022 and 1H 2023; and Congress’s attempts to improve medical diagnostics patent eligibility. It also includes a client interview with SonoThera CEO Kenneth Greenberg, an article on DOJ’s incentives for life sciences companies to self-disclose misconduct, and a Q&A with Ed Shenkan on decreasing risk from medical device concept to commercialization, as well as details on recent life sciences-focused NextGen VC Forums hosted by Wilson Sonsini and LaunchBio, the 28th annual Phoenix Conference and 2023 Life Sciences Investment Forum, and select life sciences client highlights.